ArticleJournal of gastrointestinal oncology2024

Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study.

Jianfa Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.